Rimonabant, a cannabinoid receptor 1 antagonist, protects LDL receptor deficient mice from atherosclerosis.

被引：0
|
作者：
Dol-Gleizes, Frederique [1 ]
Visentin, Virgile [1 ]
Mares, Anne-Marie [1 ]
Schaeffer, Paul [1 ]
Bono, Francoise [1 ]
机构：
[1] Sanofi Aventis, Toulouse, France
来源：
CIRCULATION | 2006年 / 114卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：259 / 259
页数：1
相关论文
共 50 条
  • [31] A murine model of accelerated atherosclerosis in diabetic LDL receptor deficient mice
    Lee, KJ
    Lu, Y
    Ginsberg, MD
    Ferran, L
    Stern, DM
    Schmidt, AM
    CIRCULATION, 1997, 96 (08) : 968 - 968
  • [32] Effect of macrophage ApoE on atherosclerosis in LDL-receptor deficient mice
    Tennert, Carsten
    Teupser, Daniel
    Mueller, Marc A.
    Wilfert, Wolfgang
    Renner-Mueller, Ingrid
    Stein, Olga
    Stein, YechezkIel
    Sippel, Albrecht E.
    Wolf, Eckhard
    Thiery, Joachim
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 361 (03) : 574 - 579
  • [33] Castration accelerates atherosclerosis in male LDL receptor-deficient mice
    Orlinska, U
    Banka, CL
    CIRCULATION, 2000, 102 (18) : 319 - 319
  • [34] Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats
    Jarbe, Torbjoern U. C.
    Li, Chen
    Vadivel, Subramanian K.
    Makriyannis, Alexandros
    PSYCHOPHARMACOLOGY, 2008, 198 (04) : 467 - 478
  • [35] Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats
    Torbjörn U. C. Järbe
    Chen Li
    Subramanian K. Vadivel
    Alexandros Makriyannis
    Psychopharmacology, 2008, 198 : 467 - 478
  • [36] A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice
    Cyrus, Tillmann
    Yao, Yuemang
    Ding, Tao
    Dogne, Jean Michel
    Pratico, Domenico
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 561 (1-3) : 105 - 111
  • [37] Effects of probucol on atherosclerosis of apoE-deficient or LDL receptor-deficient mice
    Yoshikawa, T
    Shimano, H
    Chen, Z
    Ishibashi, S
    Yamada, N
    HORMONE AND METABOLIC RESEARCH, 2001, 33 (08) : 472 - 479
  • [38] Rimonabant, a selective cannabinoid1 receptor antagonist, protects against light-induced retinal degeneration in vitro and in vivo
    Imamura, Tomoyo
    Tsuruma, Kazuhiro
    Inoue, Yuki
    Otsuka, Tomohiro
    Ohno, Yuta
    Ogami, Shiho
    Yamane, Shinsaku
    Shimazawa, Masamitsu
    Hara, Hideaki
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 803 : 78 - 83
  • [39] Bioactivation of the Cannabinoid Receptor Antagonist Rimonabant to a Cytotoxic Iminium Ion Metabolite
    Foster, Alison J.
    Prime, Lucy H.
    Gustafsson, Frida
    Temesi, David G.
    Isin, Emre M.
    Midlov, Johanna
    Castagnoli, Neal, Jr.
    Kenna, J. Gerry
    CHEMICAL RESEARCH IN TOXICOLOGY, 2013, 26 (01) : 124 - 135
  • [40] Urokinase receptor-deficiency reduces spontaneous atherosclerosis in LDL-receptor-deficient mice
    Jurk, Kerstin R.
    Dewerchin, Mieke
    Nofer, Roch
    Carmeliet, Peter
    Theilmeier, Gregor
    CIRCULATION, 2006, 114 (18) : 334 - 334
12345